

GLUCOSE MANAGEMENT PRACTICE TEST (SAMPLE)

STUDY GUIDE



**SAMPLE STUDY GUIDE
WITH LIMITED QUESTIONS**

**VISIT US ONLINE FOR
THE FULL VERSION STUDY GUIDE**

<https://glucosemgmt.examzify.com>



Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright	1
Table of Contents	2
Introduction	3
How to Use This Guide	4
Questions	5
Answers	8
Explanations	10
Next Steps	15

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

SAMPLE

- 1. Which of the following is a GLP-1 receptor agonist?**
 - A. Exenatide
 - B. Metformin
 - C. Sitagliptin
 - D. Glyburide

- 2. What is the mechanism of action of alpha-glucosidase inhibitors?**
 - A. Direct stimulation of insulin release
 - B. Delayed absorption of carbohydrates
 - C. Increased hepatic glucose production
 - D. Renal glucose excretion

- 3. An A1c of 5.9% indicates prediabetes.**
 - A. True
 - B. False
 - C. Only with fasting glucose
 - D. Only with symptoms

- 4. Which of the following are drug interactions with canagliflozin?**
 - A. Diuretics, rifampin, phenytoin, phenobarbital
 - B. ACE inhibitors and ARBs
 - C. Metformin and glyburide
 - D. Acetaminophen and ibuprofen

- 5. What is a fatal consequence of hypoglycemia?**
 - A. Increased hair growth
 - B. Brain doesn't have glucose for basic functions
 - C. Enhanced memory
 - D. Improved vision

- 6. Amylin mimetics have what impact on the absorption of oral medications?**
 - A. Delays gastric emptying but does not affect absorption
 - B. Delays PO drug absorption
 - C. Speeds up absorption of oral medications
 - D. Has no effect on gastric emptying or absorption

- 7. Which option lists a GLP-1 receptor agonist?**
- A. Exenatide, dulaglutide, liraglutide (for DM and obesity)
 - B. Metformin
 - C. Dapagliflozin
 - D. Pramlintide
- 8. Which features distinguish hyperosmolar hyperglycemic state (HHS) from diabetic ketoacidosis?**
- A. Glucose >600 mg/dL, high serum osmolality, little to no ketones, minimal acidosis (pH >7.3) and more dehydration.
 - B. Glucose >600 mg/dL with severe acidosis and high ketones.
 - C. Glucose <300 mg/dL with low osmolality.
 - D. Ketones present, acidosis severe.
- 9. Which criterion is used in the oral glucose tolerance test for diagnosing diabetes?**
- A. Fasting glucose >126 mg/dL
 - B. 2 hour plasma glucose >200 mg/dL
 - C. A1c >6.5%
 - D. Random glucose >200 mg/dL
- 10. Sulfonylureas should be avoided in which situation?**
- A. Pregnancy and lactation
 - B. Elderly
 - C. Renal impairment
 - D. None of the above

Answers

SAMPLE

1. A
2. B
3. B
4. A
5. B
6. B
7. A
8. A
9. B
10. A

SAMPLE

Explanations

SAMPLE

1. Which of the following is a GLP-1 receptor agonist?

A. Exenatide

B. Metformin

C. Sitagliptin

D. Glyburide

GLP-1 receptor agonists mimic the action of the natural incretin GLP-1 by directly activating the GLP-1 receptor. This leads to glucose-dependent enhancement of insulin secretion, suppression of glucagon, slower gastric emptying, and often weight loss. Exenatide is a synthetic analogue of GLP-1, so it fits this mechanism exactly. The other drugs act differently: Metformin lowers hepatic glucose production and improves insulin sensitivity rather than activating GLP-1 receptors. Sitagliptin inhibits the DPP-4 enzyme, which slows the breakdown of endogenous GLP-1, increasing its levels but not directly activating GLP-1 receptors itself. Glyburide, a sulfonylurea, stimulates insulin release by closing KATP channels in beta cells, independent of GLP-1 receptor signaling.

2. What is the mechanism of action of alpha-glucosidase inhibitors?

A. Direct stimulation of insulin release

B. Delayed absorption of carbohydrates

C. Increased hepatic glucose production

D. Renal glucose excretion

Alpha-glucosidase inhibitors work by blocking the intestinal brush-border enzymes that break down complex carbohydrates into absorbable glucose. By inhibiting these enzymes, carbohydrate digestion is slowed, delaying glucose absorption and blunting the post-meal rise in blood glucose. This effect is localized to the gut and does not stimulate insulin release, increase hepatic glucose production, or cause renal glucose excretion. GI side effects from undigested carbohydrates reaching the colon are common, such as gas and diarrhea.

3. An A1c of 5.9% indicates prediabetes.

A. True

B. False

C. Only with fasting glucose

D. Only with symptoms

Understanding A1c thresholds and what they mean for glucose status is the key idea here. Prediabetes is defined by an A1c in the 5.7% to 6.4% range. An A1c of 5.9% falls right within that range, so it indicates prediabetes rather than normal glucose tolerance or diabetes. Symptoms are not required for this classification; the lab value itself places someone in the prediabetes category. In practice, clinicians may repeat testing or use additional measures to confirm the overall glucose status, but the A1c level of 5.9% already identifies prediabetes.

4. Which of the following are drug interactions with canagliflozin?

A. Diuretics, rifampin, phenytoin, phenobarbital

B. ACE inhibitors and ARBs

C. Metformin and glyburide

D. Acetaminophen and ibuprofen

Canagliflozin is an SGLT2 inhibitor, so when thinking about drug interactions the focus is on effects that change its exposure or increase risks from diuresis. Diuretics can heighten the risk of volume depletion and low blood pressure when used with canagliflozin because both promote fluid loss. In addition, drugs that induce hepatic enzymes or transporters—like rifampin, phenytoin, and phenobarbital—can increase the metabolism of canagliflozin, lowering its levels and potentially reducing its glucose-lowering effect. That combination—diuretics plus enzyme inducers—best captures the known interactions with canagliflozin. The other options don't reflect meaningful pharmacokinetic interactions with canagliflozin. ACE inhibitors and ARBs are commonly used with canagliflozin and mainly require monitoring for blood pressure and kidney function rather than a direct drug–drug interaction. Metformin and glyburide can be used together with canagliflozin without a specific interaction that changes its exposure. Acetaminophen and ibuprofen do not affect canagliflozin's pharmacokinetics.

5. What is a fatal consequence of hypoglycemia?

A. Increased hair growth

B. Brain doesn't have glucose for basic functions

C. Enhanced memory

D. Improved vision

The brain relies almost entirely on glucose for its energy. When blood glucose drops, brain cells can't generate enough energy to function, leading to neuroglycopenia where brain activity falters. This energy shortage quickly affects consciousness and vital brain functions, and if hypoglycemia isn't corrected promptly, it can progress to seizures, coma, and potentially death. That's why the statement about the brain not having glucose for basic functions describes the fatal consequence of hypoglycemia. The other options describe effects that don't reflect the brain-energy crisis caused by low glucose.

6. Amylin mimetics have what impact on the absorption of oral medications?

A. Delays gastric emptying but does not affect absorption

B. Delays PO drug absorption

C. Speeds up absorption of oral medications

D. Has no effect on gastric emptying or absorption

Amylin mimetics slow gastric emptying, so the movement of chyme from the stomach into the small intestine is delayed. Since most oral medications are absorbed mainly in the small intestine, this slower transit means the drug sits in the stomach longer before absorption can begin, pushing back the onset of action and delaying peak concentrations. The total amount absorbed for many drugs may not change, but the rate is slower. Therefore, the effect is best described as delaying oral drug absorption.

7. Which option lists a GLP-1 receptor agonist?

- A. Exenatide, dulaglutide, liraglutide (for DM and obesity)
- B. Metformin
- C. Dapagliflozin
- D. Pramlintide

GLP-1 receptor agonists are incretin mimetics that activate the GLP-1 receptor to boost glucose-dependent insulin release, suppress glucagon, slow gastric emptying, and promote satiety. Exenatide, dulaglutide, and liraglutide are classic examples of this class and are used in type 2 diabetes (and some for obesity). The other options represent different drug classes: metformin lowers hepatic glucose production, dapagliflozin inhibits SGLT2 to increase urinary glucose excretion, and pramlintide is an amylin analogue; none of these are GLP-1 receptor agonists.

8. Which features distinguish hyperosmolar hyperglycemic state (HHS) from diabetic ketoacidosis?

- A. Glucose >600 mg/dL, high serum osmolality, little to no ketones, minimal acidosis (pH >7.3) and more dehydration.
- B. Glucose >600 mg/dL with severe acidosis and high ketones.
- C. Glucose <300 mg/dL with low osmolality.
- D. Ketones present, acidosis severe.

HHS is defined by very high blood glucose with pronounced dehydration and a high effective osmolality, but with little to no ketoacidosis. The insulin level is enough to suppress ketone production, so ketones are minimal and the acid-base disturbance is mild or absent (pH typically above 7.3). The extreme hyperglycemia drives osmotic diuresis, leading to substantial fluid loss and higher osmolality. That's why the best choice describes glucose often over 600 mg/dL, high serum osmolality, little to no ketones, only minimal acidosis, and more dehydration. In contrast, diabetic ketoacidosis features significant ketosis and metabolic acidosis (pH < 7.3, bicarbonate low) with variable glucose that is usually not as extremely high, and dehydration is present but not to the same extent as in HHS.

9. Which criterion is used in the oral glucose tolerance test for diagnosing diabetes?

- A. Fasting glucose >126 mg/dL
- B. 2 hour plasma glucose >200 mg/dL
- C. A1c >6.5%
- D. Random glucose >200 mg/dL

In the oral glucose tolerance test, you look at how the body handles a glucose load by measuring the glucose level two hours after drinking a fixed amount of glucose. A 2-hour plasma glucose level of 200 mg/dL or higher is diagnostic for diabetes with this test because it shows the body's tissues aren't clearing glucose efficiently after the load. The other numbers come from different tests: fasting glucose uses a 126 mg/dL threshold, A1c uses 6.5% or higher, and a random glucose of 200 mg/dL with symptoms is diagnostic in the appropriate clinical context. But for the OGTT, the key criterion is the 2-hour value at or above 200 mg/dL.

10. Sulfonylureas should be avoided in which situation?

A. Pregnancy and lactation

B. Elderly

C. Renal impairment

D. None of the above

Sulfonylureas stimulate the pancreas to release insulin, but they can cross the placenta and reach the fetus. That exposes the developing baby to the drug, which can cause fetal and neonatal hypoglycemia after birth and potential other risks. Similarly, during breastfeeding, the drug and its metabolites can pass into breast milk and may induce hypoglycemia in the nursing infant. For these safety reasons, sulfonylureas are avoided in pregnancy and lactation, with insulin being the preferred option to control blood glucose in these states. In contrast, while elderly patients or those with renal impairment require careful monitoring and sometimes dose adjustments due to higher hypoglycemia risk, these conditions do not by themselves mandate avoiding sulfonylureas.

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

<https://glucosemgmt.examzify.com>

We wish you the very best on your exam journey. You've got this!

SAMPLE